Influenza B Virus B/phuket/3073/2013 Antigen (formaldehyde Inactivated)

For adults aged 18 to 64, the standard dose of a vaccine containing the Influenza B Virus B/phuket/3073/2013 Antigen is a single 0.5 mL intramuscular injection. This is typically administered once annually, usually in the autumn months (September through November in the Northern Hemisphere) to ensure peak antibody levels during the height of the flu season. For adults aged 65 and older, a 'high-dose' or 'adjuvanted' version may be used, which contains a higher concentration of the antigen (often 60 mcg of HA per strain instead of the standard 15 mcg) to overcome age-related immunosenescence (the natural weakening of the immune system with age).

Pediatric dosing is strictly age-dependent:

• Children 6 months through 35 months: Depending on the brand, the dose may be 0.25 mL or 0.5 mL.
• Children 3 years through 17 years: The standard dose is 0.5 mL.
• Priming Dose: Children aged 6 months through 8 years who are receiving their first-ever influenza vaccination (or who have not previously received at least two doses) require a two-dose series. These doses must be administered at least 4 weeks apart to ensure the child's immune system is properly 'primed' to recognize the B/Phuket/3073/2013 antigen.

Renal Impairment

No dosage adjustment is required for patients with renal (kidney) impairment. The antigen is not cleared by the kidneys, and there is no evidence that renal dysfunction affects the safety or efficacy of the vaccine.

Hepatic Impairment

No dosage adjustment is required for patients with hepatic (liver) impairment. The metabolic processing of viral antigens occurs within the immune system and does not rely on hepatic CYP450 enzymes.

Elderly Patients

As noted, elderly patients (65+) are encouraged to receive formulations specifically designed for their age group (High-Dose or Adjuvanted), though the standard 0.5 mL dose is safe. The goal in this population is to maximize the immune response rather than adjust for toxicity.

This antigen must be administered by a qualified healthcare professional. The following guidelines apply:

1. 1Preparation: The vaccine should be shaken well before administration to ensure a homogenous suspension. It should be inspected visually for particulate matter or discoloration.
2. 2Route: Intramuscular (IM) injection only. The preferred site is the deltoid muscle of the upper arm for adults and older children. For infants and small children, the anterolateral aspect of the thigh is preferred.
3. 3Storage: The antigen is highly temperature-sensitive. It must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). It must NEVER be frozen. Exposure to freezing temperatures destroys the protein structure of the B/Phuket/3073/2013 antigen, rendering it ineffective.

Because influenza is seasonal, a 'missed dose' refers to failing to get vaccinated before the virus begins circulating in the community. If you miss the early autumn window, you can still receive the vaccine as long as the virus is still circulating (often through May). If a child misses the second dose of their initial two-dose series, it should be administered as soon as possible.

There is no clinical data regarding 'overdose' of this antigen. Accidental administration of a second dose within a short period is unlikely to cause serious harm but may increase the severity of local injection site reactions (pain, swelling). In the event of an accidental double-dose, monitor for enhanced systemic side effects like fever or malaise.

> Important: Follow your healthcare provider's dosing instructions. Do not seek vaccination more frequently than recommended by the CDC or your local health authority.

The most frequently reported side effects associated with the Influenza B Virus B/phuket/3073/2013 Antigen are localized to the site of injection. These are generally mild and resolve within 24 to 48 hours without medical intervention.

• Injection Site Pain: A dull ache in the deltoid muscle, similar to a minor bruise. This occurs in up to 65% of recipients.
• Tenderness: Sensitivity when the area is touched or when the arm is moved.
• Erythema (Redness): A small red patch at the needle entry point.
• Induration (Hardness): A firm spot under the skin where the antigen was deposited.
• Fatigue: A general feeling of tiredness or low energy as the body begins the energy-intensive process of building antibodies.
• Headache: Mild to moderate tension-type headache.

These systemic reactions indicate that the immune system is responding to the antigen:

• Myalgia (Muscle Aches): Generalized body aches, often in the back or legs.
• Arthralgia (Joint Pain): Stiffness or discomfort in the joints.
• Low-Grade Fever: Typically defined as a temperature between 100.4°F and 101.5°F.
• Chills: Feeling cold or shivering shortly after vaccination.
• Nausea: Mild stomach upset, though vomiting is rare in adults.

• Lymphadenopathy: Swelling of the lymph nodes in the armpit (axillary) on the side where the shot was given.
• Syncope (Fainting): Usually triggered by the process of injection (vasovagal response) rather than the antigen itself.
• Urticaria (Hives): A mild allergic skin rash.

While extremely rare, serious adverse events can occur. You must seek emergency medical care if you experience:

• Anaphylaxis: A severe allergic reaction characterized by swelling of the face, tongue, or throat, difficulty breathing, rapid heart rate, and a sharp drop in blood pressure.
• Guillain-Barré Syndrome (GBS): A rare neurological disorder where the body's immune system attacks the nerves. Symptoms include tingling or weakness in the feet and legs that spreads to the upper body, and in severe cases, paralysis. The estimated risk is approximately 1 to 2 additional cases per million doses administered.
• Brachial Plexitis: Severe pain and weakness in the shoulder and arm.
• High Fever: A temperature exceeding 103°F (39.4°C).

> Warning: Stop taking any further doses and call your doctor immediately if you experience any signs of a severe allergic reaction or neurological changes following administration of Influenza B Virus B/phuket/3073/2013 Antigen.

There are no known long-term side effects associated with this inactivated antigen. The proteins are cleared from the body within days, and the only lasting effect is the presence of protective antibodies and memory B-cells. There is no evidence that seasonal influenza vaccination leads to chronic health conditions or autoimmune diseases in the general population.

There are currently no FDA black box warnings for Influenza B Virus B/phuket/3073/2013 Antigen (formaldehyde Inactivated). It is considered one of the safest biological products on the market, with a safety profile established through decades of use of similar inactivated influenza antigens.

Report any unusual symptoms to your healthcare provider or via the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967.

Before receiving a vaccine containing the Influenza B Virus B/phuket/3073/2013 Antigen, it is vital to disclose your full medical history to your healthcare provider. While the antigen is inactivated and safe for most people, certain underlying conditions can increase the risk of adverse reactions or decrease the effectiveness of the immunization.

No FDA black box warnings for Influenza B Virus B/phuket/3073/2013 Antigen (formaldehyde Inactivated).

• Allergic Reactions / Anaphylaxis Risk: Patients with a history of severe allergic reactions to any component of the vaccine (including formaldehyde, which is used in the inactivation process, or trace amounts of egg protein) should not receive this antigen. Facilities must always have epinephrine and other emergency treatments available during administration.
• Guillain-Barré Syndrome (GBS): If you have ever had GBS within 6 weeks of a previous influenza vaccination, your doctor will carefully weigh the risks and benefits. In many cases, a history of GBS is a precaution that may lead to avoiding further flu shots.
• Acute Febrile Illness: Vaccination should typically be delayed in patients with moderate to severe acute illness, with or without fever. This is to avoid confusing the symptoms of the illness with potential side effects of the vaccine and to ensure the immune system can focus on responding to the antigen.
• Altered Immunocompetence: If you are taking immunosuppressant medications (e.g., high-dose corticosteroids, chemotherapy) or have an immunodeficiency disorder, your immune response to the B/Phuket/3073/2013 antigen may be diminished. You may still receive the vaccine, but it may provide less protection.

There are no specific laboratory tests (like blood counts or liver panels) required before or after receiving this antigen. However, clinical monitoring for 15 minutes post-injection is recommended by the CDC to observe for signs of syncope (fainting) or immediate allergic reactions.

This antigen has no known effect on the ability to drive or operate machinery. However, if you experience post-vaccination syncope or significant fatigue, you should wait until these symptoms resolve before performing hazardous tasks.

There is no direct interaction between alcohol and the B/Phuket/3073/2013 antigen. However, excessive alcohol consumption can suppress the immune system and may theoretically reduce the body's ability to mount an effective response to the vaccine. It is generally advisable to avoid heavy drinking for 48 hours after vaccination.

As this is a single-dose (or two-dose priming) seasonal product, 'discontinuation' is not applicable in the same way as daily medications. However, if a patient experiences a severe reaction to the first dose of a two-dose pediatric series, the second dose must be withheld.

> Important: Discuss all your medical conditions, especially any history of neurological issues or severe allergies, with your healthcare provider before starting Influenza B Virus B/phuket/3073/2013 Antigen (formaldehyde Inactivated).

There are no absolute drug-drug contraindications that make the use of Influenza B Virus B/phuket/3073/2013 Antigen 'never' possible. However, it should not be administered simultaneously with other vaccines in the same syringe. Each vaccine must be given at a different anatomical site (e.g., different arms).

• Immunosuppressants (e.g., Cyclosporine, Tacrolimus, Methotrexate): These drugs reduce the activity of the immune system. The clinical consequence is a potentially significant reduction in the efficacy of the B/Phuket/3073/2013 antigen. Patients may fail to develop protective antibody titers. Management involves timing the vaccination when immunosuppression is at its lowest point, if medically feasible.
• Corticosteroids (e.g., Prednisone): High-dose systemic steroids (equivalent to 20mg/day of prednisone for 2 weeks or more) can blunt the immune response. Low-dose, inhaled, or topical steroids do not typically interfere with the antigen.
• Chemotherapy: Cytotoxic agents that deplete white blood cells will prevent the body from responding to the antigen. Vaccination is usually recommended either 2 weeks before starting chemotherapy or between cycles when blood counts have recovered.

• Antivirals (e.g., Oseltamivir, Baloxavir): While these drugs treat the flu, they do not interfere with the inactivated B/Phuket/3073/2013 antigen. They only interact with Live Attenuated Influenza Vaccines (LAIV). Therefore, you can safely take Tamiflu and get an inactivated flu shot.
• Anticoagulants (e.g., Warfarin, Apixaban): These do not interact with the antigen itself, but they increase the risk of hematoma (bruising/bleeding) at the injection site. Use a fine-gauge needle and apply firm pressure for at least 2 minutes after the shot.

There are no known interactions with dairy, caffeine, grapefruit, or high-fat meals. The antigen's processing is entirely independent of the digestive system.

• Echinacea and Elderberry: Some patients take these to 'boost' the immune system. While there is no evidence of harm, there is also no clinical data suggesting they improve the response to the B/Phuket/3073/2013 antigen.
• St. John's Wort: Does not interact with this biological antigen.

• False Positive HIV/HCV/HTLV-1 Tests: Rarely, influenza vaccination has been associated with transient false-positive results on certain enzyme immunoassays (ELISA) for HIV-1, Hepatitis C, and HTLV-1. This is due to the production of cross-reactive IgM antibodies. If a positive result occurs shortly after vaccination, a more specific confirmatory test (like a Western Blot or PCR) should be performed.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect your immune system.

Influenza B Virus B/phuket/3073/2013 Antigen (formaldehyde Inactivated) must NEVER be used in the following circumstances:

• Severe Allergic Reaction (Anaphylaxis) to a Previous Flu Vaccine: If a patient has had a life-threatening reaction to any influenza vaccine in the past, regardless of the specific strain, they should not receive this antigen.
• Severe Allergy to Vaccine Components: This includes a known systemic hypersensitivity to formaldehyde (used to inactivate the virus), polymyxin, or neomycin (trace antibiotics used during manufacturing).
• Infants under 6 Months: The safety and efficacy of this antigen have not been established in infants younger than 6 months. Their immune systems are generally unable to mount a sufficient response to the antigen, and they rely on maternal antibodies.

Conditions requiring careful risk-benefit analysis include:

• History of Guillain-Barré Syndrome (GBS): As mentioned, if GBS occurred within 6 weeks of a previous flu shot, the risk of recurrence is a concern.
• Moderate to Severe Acute Illness: Vaccination should be deferred until the patient has recovered to ensure the immune system is 'available' to respond to the antigen and to avoid diagnostic confusion regarding side effects.
• Egg Allergy: Historically, egg allergy was a major contraindication. However, current CDC and AAAAI guidelines state that most people with egg allergies (even severe ones) can safely receive egg-based flu vaccines in a standard medical setting. For those with extreme 'anaphylactic' egg allergy, cell-based or recombinant vaccines that do not contain the B/Phuket/3073/2013 egg-derived antigen may be preferred.

There is potential for cross-sensitivity among different brands of influenza vaccines if they use the same stabilizing agents or antibiotics. If you are allergic to one brand of flu shot, your doctor will check the 'Ingredients' list of the vaccine containing B/Phuket/3073/2013 to ensure it does not contain the same excipients.

> Important: Your healthcare provider will evaluate your complete medical history and prior vaccine reactions before prescribing Influenza B Virus B/phuket/3073/2013 Antigen (formaldehyde Inactivated).

Influenza B Virus B/phuket/3073/2013 Antigen is considered safe and is strongly recommended for pregnant individuals. Pregnancy increases the risk of severe complications from Influenza B, including pneumonia and premature labor.

• Trimester-Specific Data: The vaccine can be administered in any trimester. Extensive observational studies have shown no increased risk of birth defects, miscarriages, or stillbirths.
• Passive Immunity: A significant benefit of vaccinating the mother is that the antibodies she produces against the B/Phuket/3073/2013 antigen cross the placenta, providing the newborn with 'passive' protection for several months after birth, a period when the infant is too young to be vaccinated themselves.

Inactivated influenza antigens do not pass into breast milk in a way that would affect the infant. Breastfeeding mothers can safely receive the vaccine. In fact, antibodies (IgA) may be passed through breast milk, potentially offering additional respiratory protection to the nursing child.

As detailed in the dosage section, this antigen is approved for children 6 months and older. It is a critical part of the pediatric wellness schedule. Children under 5, and especially those under 2, are at high risk for flu-related hospitalizations. The B/Phuket/3073/2013 antigen has been shown to be immunogenic and well-tolerated in this population. It is NOT approved for infants under 6 months.

Patients aged 65 and older are at the highest risk of mortality from Influenza B. While the standard dose of B/Phuket/3073/2013 antigen is safe, this population often has a 'suboptimal' immune response. Therefore, 'Enhanced' vaccines (High-Dose or Adjuvanted) are preferred for this group. There are no specific safety concerns unique to the elderly other than a slightly higher rate of local injection site reactions with the high-dose versions.

Patients with chronic kidney disease (CKD) or those on dialysis are considered 'high risk' for flu complications. The antigen is safe for use in these patients. Because it is not cleared by the kidneys, no dose reduction is necessary, though the immune response may be slightly weaker than in healthy individuals.

Patients with cirrhosis or other liver diseases can safely receive this antigen. There is no evidence of hepatotoxicity, and the liver is not involved in the processing of the inactivated viral proteins.

> Important: Special populations require individualized medical assessment. Always consult with a specialist if you have a complex medical condition.

Influenza B Virus B/phuket/3073/2013 Antigen (formaldehyde Inactivated) functions as an immunogenic stimulus. The 'active' part of the antigen is the Hemagglutinin (HA) protein. In nature, the HA protein allows the Influenza B virus to attach to sialic acid receptors on the surface of human respiratory epithelial cells. By introducing inactivated HA proteins into the muscle, the body produces 'neutralizing antibodies.' These antibodies are shaped specifically to 'lock' onto the HA protein of the B/Phuket/3073/2013-like viruses. When a real virus enters the body, these antibodies coat the virus, preventing it from attaching to and infecting human cells.

• Onset of Effect: Protective antibody titers (typically defined as a hemagglutination inhibition [HI] titer of 1:40 or greater) are usually reached within 2 to 3 weeks following vaccination.
• Duration of Effect: Immunity typically lasts for 6 to 12 months. This is why annual vaccination is required—not just because the virus changes, but because antibody levels naturally decline over time.
• Tolerance: There is no pharmacological tolerance; however, 'original antigenic sin' is a phenomenon where the body's response to new strains is influenced by its first exposure to an influenza antigen.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intramuscular) |

| Protein Binding | N/A (Viral Protein) |

| Half-life (Antigen) | ~24-48 hours (Cleared by APCs) |

| Tmax (Antibody) | 14-21 days |

| Metabolism | Proteolysis in Lymphatic System |

| Excretion | Cellular clearance |

The antigen is a purified fraction of the Influenza B virus. The virus is grown in eggs, inactivated with formaldehyde, and then chemically disrupted (split) using detergents like Triton X-100 to reduce reactogenicity while maintaining immunogenicity. The final product is a suspension of viral sub-units, primarily HA and NA proteins.

It is classified as a Standardized Chemical Allergen [EPC] and a Viral Vaccine Antigen. It is specifically part of the Yamagata lineage of Influenza B, which is one of the two distinct lineages (the other being Victoria) that have circulated globally since the 1980s.